| abstract |
The present invention relates to a thiocarbamate derivative of formula (I) that is useful as an A2A adenosine receptor (A2AR) inhibitor. In particular, the present invention comprises a pharmaceutical composition comprising an A2A inhibitor of formula (I) and a lipid carrier such as lauroyl macrogol-32 glyceride, D-α-tocopherol-polyethylene glycol-1000 succinate, or a mixture thereof. Regarding. The pharmaceutical composition of the present invention is particularly useful for oral administration in the treatment of cancer. The present invention also relates to a combination comprising an A2A receptor inhibitor of formula (I) and an anticancer agent. Anti-cancer agents are, for example, immunotherapeutic agents such as checkpoint inhibitors. The present invention further relates to pharmaceutical compositions and parts kits comprising such combinations. In addition, the combinations of the invention are particularly useful for the treatment and / or prevention of cancer. |